

Josep M Llovet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2650438/publications.pdf>

Version: 2024-02-01

280
papers

106,934
citations

701

121
h-index

394

279
g-index

296
all docs

296
docs citations

296
times ranked

50339
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	27.0	12,004
2	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	3.7	6,153
3	Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. <i>Journal of Hepatology</i> , 2001, 35, 421-430.	3.7	3,959
4	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012, 379, 1245-1255.	13.7	3,897
5	Hepatocellular carcinoma. <i>Lancet, The</i> , 2003, 362, 1907-1917.	13.7	3,886
6	Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2010, 30, 052-060.	3.6	3,250
7	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <i>Lancet, The</i> , 2002, 359, 1734-1739.	13.7	3,172
8	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
9	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	30.5	2,757
10	Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. <i>Hepatology</i> , 2003, 37, 429-442.	7.3	2,646
11	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2009, 10, 35-43.	10.7	1,920
12	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. <i>Hepatology</i> , 1999, 30, 1434-1440.	7.3	1,869
13	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	30.5	1,863
14	Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 698-711.	6.3	1,545
15	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	21.4	1,372
16	Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 599-616.	27.6	1,308
17	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3129-3140.	4.1	1,237
18	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 282-296.	10.7	1,202

#	ARTICLE	IF	CITATIONS
19	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	3.7	1,151
20	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
21	Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. <i>Hepatology</i> , 1999, 29, 62-67.	7.3	1,044
22	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	3.6	1,043
23	Prognostic prediction and treatment strategy in hepatocellular carcinoma. <i>Hepatology</i> , 2002, 35, 519-524.	7.3	1,003
24	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	1.3	980
25	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.9	978
26	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1312-1327.	7.3	899
27	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 97-104.	7.3	884
28	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007, 46, 474-481.	3.7	864
29	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	1.3	838
30	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	10.7	809
31	Lin28 promotes transformation and is associated with advanced human malignancies. <i>Nature Genetics</i> , 2009, 41, 843-848.	21.4	742
32	Novel advancements in the management of hepatocellular carcinoma in 2008. <i>Journal of Hepatology</i> , 2008, 48, S20-S37.	3.7	739
33	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
34	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2960-2970.	1.6	723
35	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. <i>Hepatology</i> , 2001, 33, 1124-1129.	7.3	698
36	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	1.3	650

#	ARTICLE	IF	CITATIONS
37	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
38	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	1.3	644
39	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 110-118.	1.3	644
40	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
41	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	7.3	632
42	The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2004, 10, S115-S120.	2.4	616
43	Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2013, 144, 512-527.	1.3	600
44	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.9	589
45	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	3.7	567
46	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3509-3516.	1.6	544
47	Focus on hepatocellular carcinoma. <i>Cancer Cell</i> , 2004, 5, 215-219.	16.8	523
48	A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 850-855.	1.3	517
49	Chemoembolization for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S179-S188.	1.3	504
50	Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2290-2300.	7.0	503
51	Î²-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	9.4	498
52	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	3.6	491
53	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. <i>Hepatology</i> , 1998, 27, 1578-1583.	7.3	482
54	SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 559-566.	1.6	479

#	ARTICLE	IF	CITATIONS
55	Updated treatment approach to hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2005, 40, 225-235.	5.1	466
56	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	27.6	456
57	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	1.3	438
58	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012, 56, 1330-1335.	3.7	436
59	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 293-313.	17.8	428
60	Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. <i>Hepatology</i> , 2000, 31, 1019-1021.	7.3	413
61	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1352-1360.	7.3	409
62	Targeted Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1410-1426.	1.3	408
63	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	4.1	403
64	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. <i>Hepatology</i> , 2003, 38, 1034-1042.	7.3	401
65	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	1.3	389
66	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	1.3	379
67	Mutant IDH inhibits HNF-4 β to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014, 513, 110-114.	27.8	367
68	DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	7.3	367
69	Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. <i>Hepatology</i> , 1998, 27, 1572-1577.	7.3	357
70	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1386-1395.	10.7	357
71	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	7.3	347
72	Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. <i>Clinical Cancer Research</i> , 2014, 20, 2072-2079.	7.0	341

#	ARTICLE	IF	CITATIONS
73	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	3.9	327
74	Resection of hepatocellular cancer ≤2 cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	7.3	326
75	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	1.3	302
76	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. <i>Journal of Clinical Investigation</i> , 2009, 119, 465-477.	8.2	298
77	mRECIST for HCC: Performance and novel refinements. <i>Journal of Hepatology</i> , 2020, 72, 288-306.	3.7	292
78	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 34-42.	17.8	277
79	Major achievements in hepatocellular carcinoma. <i>Lancet, The</i> , 2009, 373, 614-616.	13.7	275
80	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	3.6	267
81	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 1294-1300.	2.4	263
82	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. <i>Gastroenterology</i> , 2012, 143, 1660-1669.e7.	1.3	262
83	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 196-209.	16.8	261
84	Platelet GPIb-IX is a mediator and potential interventional target for NASH and subsequent liver cancer. <i>Nature Medicine</i> , 2019, 25, 641-655.	30.7	259
85	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	7.0	251
86	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. <i>Hepatology</i> , 2000, 31, 54-58.	7.3	242
87	Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. <i>Hepatology</i> , 2001, 33, 1073-1079.	7.3	242
88	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240
89	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	7.3	235
90	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. <i>Journal of Hepatology</i> , 2007, 47, 527-537.	3.7	231

#	ARTICLE	IF	CITATIONS
91	Staging systems in hepatocellular carcinoma. <i>Hpb</i> , 2005, 7, 35-41.	0.3	230
92	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	12.8	230
93	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	12.2	229
94	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. <i>Cell Reports</i> , 2015, 10, 1692-1707.	6.4	213
95	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockade. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	3.7	211
96	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	3.7	206
97	Hepatocellular carcinoma: present status and future prospects. <i>Journal of Hepatology</i> , 2003, 38, 136-149.	3.7	205
98	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	1.3	205
99	Genome-Wide Methylation Analysis and Epigenetic Unmasking Identify Tumor Suppressor Genes in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2013, 145, 1424-1435.e25.	1.3	204
100	Experimental models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 858-879.	3.7	203
101	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 1286-1296.	12.1	198
102	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	1.3	195
103	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	12.1	195
104	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009, 27, 264-274.	17.5	194
105	Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. <i>Hepatology</i> , 2004, 40, 699-707.	7.3	189
106	Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 291-300.	7.0	185
107	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	3.7	181
108	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017, 66, 1166-1172.	3.7	178

#	ARTICLE	IF	CITATIONS
109	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 921-929.	3.7	173
110	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	16.8	172
111	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	3.7	164
112	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 530-540.	12.1	161
113	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 1731-1741.	1.3	160
114	Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. <i>Cancer Cell</i> , 2021, 39, 866-882.e11.	16.8	159
115	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	9.4	157
116	Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC. <i>Clinical Cancer Research</i> , 2019, 25, 2021-2023.	7.0	152
117	Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. <i>Journal of Hepatology</i> , 1998, 28, 307-313.	3.7	150
118	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	3.7	150
119	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. <i>Hepatology</i> , 2003, 38, 1034-1042.	7.3	142
120	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	3.7	133
121	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	7.3	129
122	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	13.2	126
123	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	1.3	123
124	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 1222-1231.	3.7	121
125	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	3.7	120
126	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 186-194.	2.3	118

#	ARTICLE	IF	CITATIONS
127	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. <i>Clinical Cancer Research</i> , 2010, 16, 4688-4694.	7.0	114
128	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	3.7	111
129	Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. <i>Journal of Hepatology</i> , 1997, 26, 88-95.	3.7	109
130	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	3.7	109
131	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	1.3	109
132	Mutational landscape of HCC—the end of the beginning. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 73-74.	27.6	108
133	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	12.1	108
134	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. <i>Gastroenterology</i> , 2016, 151, 1192-1205.	1.3	103
135	Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. <i>Liver Transplantation</i> , 2003, 9, 700-702.	2.4	99
136	Chemoembolization for intermediate HCC: Is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012, 56, 984-986.	3.7	99
137	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.9	99
138	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 134, 1521-1531.	1.3	96
139	Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 2652-2669.	7.3	95
140	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4152-TPS4152.	1.6	94
141	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	1.3	91
142	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	12.1	90
143	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	5.9	89
144	Induction of hepatocellular carcinoma by in vivo gene targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11264-11269.	7.1	88

#	ARTICLE	IF	CITATIONS
145	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 1824-1826.	7.0	86
146	Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. <i>Journal of Hepatology</i> , 2020, 73, 328-341.	3.7	82
147	Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. <i>Journal of Hepatology</i> , 2008, 49, 581-588.	3.7	80
148	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	5.9	77
149	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4003-4003.	1.6	77
150	Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA154-LBA154.	1.6	76
151	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	3.7	75
152	Molecular approaches to treatment of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S264-S272.	0.9	75
153	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	12.1	70
154	Effect of HCV clearance with direct-acting antiviral agents on HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 561-562.	17.8	67
155	CXCR2 inhibition enables NASH-HCC immunotherapy. <i>Gut</i> , 2022, 71, 2093-2106.	12.1	66
156	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	3.7	64
157	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63
158	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	6.4	62
159	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. <i>Gastroenterology</i> , 2019, 157, 1383-1397.e11.	1.3	62
160	Treatment of hepatocellular carcinoma: is there an optimal strategy?. <i>Cancer Treatment Reviews</i> , 2003, 29, 99-104.	7.7	61
161	Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. <i>Molecular Therapy</i> , 2021, 29, 680-690.	8.2	61
162	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. <i>Current Opinion in Oncology</i> , 2008, 20, 444-453.	2.4	60

#	ARTICLE	IF	CITATIONS
163	Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 560-562.	16.8	60
164	Time to evolve trial design after everolimus failure. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 506-507.	27.6	53
165	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with <i>EGFR</i> . <i>Hepatology</i> , 2013, 57, 120-130.	7.3	52
166	A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4519-4519.	1.6	50
167	Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling. <i>Seminars in Liver Disease</i> , 2006, 26, 373-384.	3.6	48
168	Percutaneous ethanol injection for hepatocellular carcinoma: Alive or dead?. <i>Journal of Hepatology</i> , 2005, 43, 377-380.	3.7	47
169	Obesity, Inflammatory Signaling, and Hepatocellular Carcinoma—An Enlarging Link. <i>Cancer Cell</i> , 2010, 17, 115-117.	16.8	47
170	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	3.6	47
171	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379.	2.4	47
172	HCC surveillance: Who is the target population?. <i>Hepatology</i> , 2003, 37, 507-509.	7.3	46
173	Early diagnosis and treatment of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 991-1008.	2.4	45
174	Treatment of hepatocellular carcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 431-441.	0.8	44
175	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 120-130.	4.9	43
176	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α -fetoprotein. <i>Lancet Oncology</i> , The, 2019, 20, e191.	10.7	42
177	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	7.3	42
178	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	12.1	42
179	Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. <i>Liver Transplantation</i> , 2004, 10, 1391-1397.	2.4	40
180	TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 685-687.	3.7	40

#	ARTICLE	IF	CITATIONS
181	Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. <i>European Radiology</i> , 2017, 27, 4472-4481.	4.5	40
182	Carcinogen-induced hepatic tumors in KLF6+/Δ mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011, 54, 522-531.	7.3	39
183	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	3.7	39
184	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	6.4	39
185	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2449-2460.	7.0	39
186	p27Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2003, 38, 591-597.	3.7	38
187	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014, 32, 4006-4006.	1.6	38
188	Molecular profiling to predict hepatocellular carcinoma outcome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 101-103.	3.0	37
189	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. <i>Journal of Hepatology</i> , 2008, 49, 1-5.	3.7	35
190	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	7.0	35
191	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	2.0	35
192	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. <i>American Journal of Transplantation</i> , 2020, 20, 220-230.	4.7	33
193	Non-surgical therapies of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 505-513.	1.6	32
194	Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 833-835.	1.6	32
195	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012, 56, 1361-1370.	7.3	31
196	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31
197	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 104-109.	3.7	30
198	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2000, 33, 423-429.	3.7	29

#	ARTICLE	IF	CITATIONS
199	Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There. <i>Seminars in Liver Disease</i> , 2006, 26, 248-253.	3.6	29
200	Prognostic Assessment and Evaluation of the Benefits of Treatment. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S138-S142.	2.2	28
201	Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. <i>Journal of Clinical Ultrasound</i> , 2003, 31, 119-128.	0.8	28
202	Translating 'omics' results into precision medicine for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 571-572.	17.8	28
203	Liver transplantation in hepatocellular carcinoma. <i>Transplant International</i> , 2005, 18, 278-282.	1.6	27
204	A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. <i>Hepatology</i> , 2011, 54, 2198-2207.	7.3	27
205	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
206	Nonsurgical treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2000, 6, s11-s15.	2.4	24
207	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	12.1	24
208	Unresectable Hepatocellular Carcinoma: Meta-Analysis of Arterial Embolization [letter]. <i>Radiology</i> , 2004, 230, 300-302.	7.3	23
209	Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified?. <i>Clinics in Liver Disease</i> , 2005, 9, 315-328.	2.1	23
210	New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 56-61.	2.1	23
211	Prognosis of hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2002, 49, 7-11.	0.5	23
212	Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing. <i>Journal of Hepatology</i> , 2006, 44, 1013-1016.	3.7	22
213	Beta-catenin cleavage enhances transcriptional activation. <i>Scientific Reports</i> , 2018, 8, 671.	3.3	22
214	Two Decades of Advances in Hepatocellular Carcinoma Research. <i>Seminars in Liver Disease</i> , 2010, 30, 001-002.	3.6	21
215	Locoregional treatments for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, 611-622.	2.4	20
216	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S67-S71.	2.4	20

#	ARTICLE	IF	CITATIONS
217	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021, 74, 816-834.	7.3	20
218	Clinical and molecular classification of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2007, 13, S13-S16.	2.4	19
219	Genome-scale metabolic models for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 336-337.	17.8	19
220	Integration of genomic information in the clinical management of HCC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 831-842.	2.4	19
221	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	7.0	19
222	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. <i>Hepatology</i> , 2002, 36, 986-992.	7.3	18
223	Gene expression profiles in hepatocellular carcinoma: not yet there. <i>Journal of Hepatology</i> , 2004, 41, 336-339.	3.7	18
224	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	4.5	18
225	Lymphotoxins: New Targets for Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 272-273.	16.8	17
226	Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4100-4100.	1.6	17
227	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. <i>Liver Transplantation</i> , 2006, 12, 1747-1754.	2.4	16
228	Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1121-1123.	6.3	16
229	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 2416-2419.	7.3	16
230	Ras- and Wnt-Independent Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner. <i>Hepatology Communications</i> , 2019, 3, 1496-1509.	4.3	15
231	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	3.5	15
232	Prognostic prediction in HCC: Did anybody expect it to be easy?. <i>Hepatology</i> , 2004, 39, 551-552.	7.3	14
233	Expanding HCC criteria for liver transplant: The urgent need for prospective, robust data. <i>Liver Transplantation</i> , 2006, 12, 1741-1743.	2.4	14
234	Smoking, Hepatitis B Virus Infection, and Development of Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1642-1643.	6.3	14

#	ARTICLE	IF	CITATIONS
235	miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 138, 1202-1204.	1.3	13
236	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	3.9	13
237	Evidence-based medicine in the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S428-S433.	2.8	12
238	HCC Is promoted by bacterial translocation and TLR-4 signaling: A new paradigm for chemoprevention and management. <i>Hepatology</i> , 2012, 56, 1998-2000.	7.3	12
239	Sunitinib and the benefits of a negative study. <i>Lancet Oncology</i> , The, 2009, 10, 743-744.	10.7	11
240	Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. <i>Lancet Oncology</i> , The, 2018, 19, e69.	10.7	11
241	Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. <i>Frontiers in Oncology</i> , 2018, 8, 220.	2.8	11
242	Hepatocellular Carcinoma: Patients With Increasing Alpha-Fetoprotein But No Mass on Ultrasound. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 29-35.	4.4	10
243	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	4.9	9
244	Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1827-1829.	7.0	9
245	A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A ₃ adenosine receptor agonist (A ₃ AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2503-2503.	1.6	9
246	Hippo Tumor Suppressor Pathway: Novel Implications for the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 139, 692-694.	1.3	8
247	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	7.0	8
248	Intrahepatic Bleeding due to Undifferentiated (Embryonal) Hepatic Sarcoma. <i>Journal of Hepatology</i> , 2000, 32, 361.	3.7	7
249	Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies?. <i>Journal of Hepatology</i> , 2013, 59, 882-884.	3.7	7
250	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH,) <i>Tj ETQq0 0 0 1gBT /Overlock 10 Tf</i>		
251	Sclerosing Hepatic Carcinoma in Non-cirrhotic Liver Resembling Metastatic Adenocarcinoma. <i>Journal of Hepatology</i> , 1999, 30, 161.	3.7	6
252	Expected developments in hepatology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 957-970.	2.4	6

#	ARTICLE	IF	CITATIONS
253	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. <i>Journal of Hepatology</i> , 2012, 57, 213-214.	3.7	6
254	microRNAs and the MYC Network: A Major Piece in the Puzzle of Liver Cancer. <i>Gastroenterology</i> , 2011, 140, 2138-2140.	1.3	5
255	Hepatocellular Carcinoma Enters the Sequencing Era. <i>Gastroenterology</i> , 2011, 141, 1943-1945.	1.3	5
256	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	3.9	5
257	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	7.7	5
258	Current management of liver cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 444-446.	2.2	4
259	Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1557-1558.	6.3	4
260	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. <i>Journal of Clinical Oncology</i> , 2020, 38, 549-549.	1.6	4
261	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1198-1200.	3.7	3
262	Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made". <i>Journal of Hepatology</i> , 2017, 67, 196-197.	3.7	3
263	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2022, 16, 665-682.	4.6	3
264	Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation. <i>Liver Transplantation</i> , 2015, 21, S25-S26.	2.4	2
265	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS478-TPS478.	1.6	2
266	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4145-TPS4145.	1.6	2
267	Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 586-586.	1.6	2
268	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS494-TPS494.	1.6	2
269	Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs. <i>Clinical Cancer Research</i> , 2022, 28, 3405-3407.	7.0	2
270	Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4084-4084.	1.6	1

#	ARTICLE	IF	CITATIONS
271	HCC •Medical treatment before and after liver transplantation. Liver Transplantation, 2010, 16, S12.	2.4	0
272	Reply to X. Qi et al. Journal of Clinical Oncology, 2014, 32, 968-969.	1.6	0
273	Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.. Journal of Clinical Oncology, 2021, 39, 4146-4146.	1.6	0
274	RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).. Journal of Clinical Oncology, 2014, 32, TPS4156-TPS4156.	1.6	0
275	Abstract B42: RAS mutations detected by cell-free plasma DNA (BEAMing) assay may portend a favorable response to refametinib +/- sorafenib in hepatocellular carcinoma. , 2014, , .		0
276	Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.. Journal of Clinical Oncology, 2015, 33, 4084-4084.	1.6	0
277	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. Journal of Clinical Oncology, 2018, 36, 3076-3076.	1.6	0
278	Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).. Journal of Clinical Oncology, 2020, 38, 544-544.	1.6	0
279	Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.. Journal of Clinical Oncology, 2020, 38, 569-569.	1.6	0
280	Addition of tyrosine kinase inhibitors (TKIs) in patients (pts) with unresectable hepatocellular carcinoma (HCC) who progress on first-line immunotherapy (IO).. Journal of Clinical Oncology, 2022, 40, e16193-e16193.	1.6	0